Dr. Raymond Douglas, an oculoplastic surgeon, discusses the approval of TEPEZZA™ (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED), the first and only FDA-approved medicine for the treatment of TED. The FDA approval of TEPEZZA™ is supported by a robust body of clinical evidence, including statistically significant, positive results from the Phase 2 clinical study, as well as the Phase 3 confirmatory clinical study OPTIC. Dr. Douglas previously presented at the American College of Rheumatology (ACR) 2019 annual meeting, sharing integrated, pooled phase 2/phase 3 clinical study data that further substantiates that teprotumumab improves the debilitating effects of active TED, including proptosis (eye bulging), diplopia (double vision), quality of life (QoL) and clinical activity score (CAS). He is joined by Wendy a participant in the TEPEZZA™ trial who saw an improvement in her eye bulging among other symptoms.
Raymond Douglas MD Ph.D. is a globally renowned board-certified oculoplastic surgeon in Beverly Hills, CA. Dr. Douglas graduated with academic distinction from the University of Pennsylvania, where he also began his medical training and Ph.D. in immunology and autoimmune inflammatory disorders. He went on to complete a sub-specialized fellowship in Orbital Facial Plastic and reconstructive surgery at the UCLA Jules Stein Eye Institute. To date, he has held several prestigious positions at the UCLA School of Medicine, Harbor-UCLAMedical Center, Greater Los Angeles Veterans Hospital, VeteransAdministration Ann Arbor Healthcare System, and the University of Michigan Kellogg Eye Center. Currently, he is also Chief Medical Officer for FlowmetricInc., a medical device company developing aging and inflammation testing for the consumer market to launch in 2020. With extensive training and focused experience, Dr. Douglas [aka “The” eyeguy] is the leader in customized and innovative approaches to both highly complex corrective and cosmetic treatments. One of the foremost leaders treating difficult cases of disfigurement due to thyroid-associated eye diseases, he is respected for both reconstructive and cosmetics arts of facial plastics by top industry peers. While traditional surgery only addressed the functional[eye] issues of the disease, Dr. Douglas pioneered specific surgical techniques(aesthetic orbital decompression) that address aesthetics and function along with an anti-inflammatory lifestyle to provide patients with the most significant cosmetic improvements and life-changing results. While Dr. Douglas honed his skills on the most difficult thyroid-associated eye disease patients, his technically precise and artistic corrective approaches along with the development of safer treatments with less scarring and significantly faster recoveries elevated his level of elite cosmetic facial surgeries and anti-aging. Currently, Dr. Douglas is the Director of the orbital and Thyroid Eye Disease program at the world-renowned Cedars-Sinai Medical Center in Los Angeles.
To help provide care to more patients with thyroid-associated eye diseases and autoimmune inflammatory disorders resulting in facial disfigurements vision impairments globally, Dr. Douglas recently opened a practice in Shanghai, China. In addition to his private practice, Dr. Douglas is also a clinical research author and educator, widely recognized for groundbreaking work on non-surgical treatments for Graves’ or thyroid-associated orbitopathy. He is the principal investigator for amulti-center international clinical trial (23 centers) that recently published positive results in the New England Journal ofMedicine on a new drug, Teprotumumab [Tepro] with Horizon Pharmaceutical, for the treatment of TED. The largest clinical trial ever conducted for a biologic in thyroid eye disease just released a Phase 3 confirmation on March 1, 2019. Set to process for FDA approvals processes by 2020, the FDA called the drug a remarkable “breakthrough therapy”.Dr. Douglas co-founded the International Thyroid Eye Disease Society to formulate international trials and has published more than 100 peer-reviewed articles and textbook chapters on Thyroid Eye Disease as well as authored a definitive textbook on autoimmune disease and anti-inflammatory care. Furthermore, Dr. Douglas has authored articles and textbook chapters on aesthetic eyelid procedures, including revision surgery technique to address poor outcomes following blepharoplasty.Dr. Douglas has a core belief that medicine and the need for surgery should be combined with a holistic approach to overall health and beauty. A proponent of an anti-inflammatory lifestyle for health, wellness longevity, and preventative medicine, Dr.Douglas is writing a book on the subject and will be opening an Infusion Wellness Center focused on inflammation testing and issues, analysis, longevity, and care. Dr. Douglas currently sees patients nationally and internationally and is committed to providing each patient with an individualized treatment plan on how to best restore their health, vitality, and appearance.